1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cholinergic Urticaria: Subtype Classification and Clinical Approach

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cholinergic urticaria (CholU) is a subtype of chronic inducible urticaria with a chief complaint of itching and/or stinging, painful papular wheals that develop simultaneously with sweating. This review specifically focuses on several subtypes of CholU and specifically investigates the relationship between CholU and anhidrosis. We review recent publications and update the evidence around CholU, including the epidemiology, clinical features, diagnostic approaches, physiopathology, subtype classification, and therapeutic approaches. Multiple mechanisms contribute in a complex manner to the development of CholU, including histamine, sweat allergy, cholinergic-related substances, poral occlusion, and hypohidrosis/anhidrosis. A new schematic of the currently known pathological conditions has been created. Specific methods for diagnosing CholU, a provocation test, and evaluation methods for disease severity/activity and disease burden of CholU are summarized. The characteristics of the diseases that should be differentiated from CholU and examination methods are also summarized. The primary finding of this review is that CholU should be categorized based on the etiology and clinical characteristics of each subtype to properly manage and treat the disease. This categorization leads to improvement of therapeutic resistance status of this disease. In particular, a sweating abnormality should be given more attention when examining patients with CholU. Because CholU is not a homogeneous disease, its subtype classification is important for selection of the most suitable therapeutic method. Further elucidation of the pathophysiology of each subtype is expected.

          Related collections

          Most cited references84

          • Record: found
          • Abstract: found
          • Article: not found

          The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision.

          These recommendations for the definition, diagnosis and management of chronic inducible urticaria (CIndU) extend, revise and update our previous consensus report on physical urticarias and cholinergic urticaria (Allergy, 2009). The aim of these recommendations is to improve the diagnosis and management of patients with CIndU. Our recommendations acknowledge the latest changes in our understanding of CIndU, and the available therapeutic options, as well as the development of novel diagnostic tools.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.

            Omalizumab has emerged as a novel and effective treatment option for patients with antihistamine-resistant chronic urticaria. It is unclear whether patients with recurrent urticaria symptoms after discontinuation of omalizumab treatment can benefit from retreatment. To assess the response of patients with chronic urticaria who receive omalizumab retreatment. Retrospective analyses were conducted of outpatients treated at an urticaria specialist center of a university hospital. Participants included 25 consecutive patients (aged 18-74 years; 18 women) with chronic spontaneous urticaria, chronic inducible urticaria, or both who showed complete response to omalizumab treatment, experienced relapse after discontinuation of treatment, and received retreatment with omalizumab. Subcutaneous treatment with omalizumab (150-600 mg/mo). Response after retreatment was assessed by the urticaria activity score in patients with chronic spontaneous urticaria and by trigger threshold testing (in patients with cold urticaria or symptomatic dermographism) and/or a carefully determined history (in patients with cholinergic urticaria, solar urticaria, or pressure urticaria). Adverse events were documented. All patients experienced complete response after retreatment. None of the patients reported relevant adverse events during omalizumab treatment and retreatment. Omalizumab retreatment is effective and safe in patients with chronic urticaria who have benefited from initial omalizumab treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients.

              Sweat is a major aggravating factor of atopic dermatitis (AD) and approximately 80% of patients with AD show type I hypersensitivity against sweat.
                Bookmark

                Author and article information

                Contributors
                atsushi.fukunaga@ompu.ac.jp
                Journal
                Am J Clin Dermatol
                Am J Clin Dermatol
                American Journal of Clinical Dermatology
                Springer International Publishing (Cham )
                1175-0561
                1179-1888
                15 September 2022
                : 1-14
                Affiliations
                [1 ]GRID grid.31432.37, ISNI 0000 0001 1092 3077, Division of Dermatology, Department of Internal Related, , Kobe University Graduate School of Medicine, ; Chuo-ku, Kobe, Japan
                [2 ]Department of Dermatology, Division of Medicine for Function and Morphology of Sensory Organs, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686 Japan
                [3 ]GRID grid.416289.0, ISNI 0000 0004 1772 3264, Department of Dermatology, , Kobe City Nishi-Kobe Medical Center, ; 5-7-1 Koji-Dai Nishi-ku, Kobe, 651-2273, Japan
                Author information
                http://orcid.org/0000-0003-2026-8154
                http://orcid.org/0000-0002-5244-0871
                http://orcid.org/0000-0001-8670-4997
                http://orcid.org/0000-0002-8530-1720
                http://orcid.org/0000-0003-0364-711X
                http://orcid.org/0000-0002-2468-7535
                Article
                728
                10.1007/s40257-022-00728-6
                9476404
                36107396
                648200af-deae-48d0-a3ef-db5b4dfc52da
                © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 26 August 2022
                Funding
                Funded by: JSPS KAKENHI
                Award ID: 20K08651
                Award Recipient :
                Categories
                Review Article

                Comments

                Comment on this article